

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6824614

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
JDS THERAPEUTICS, LLC		07/15/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	NUTRITION 21, LLC	
<b>Street Address:</b>	500 MAMARONECK AVE.	
<b>Internal Address:</b>	SUITE 510	
<b>City:</b>	HARRISON	
<b>State/Country:</b>	NEW YORK	
<b>Postal Code:</b>	10528	
<b>PROPERTY NUMBERS Total: 29</b>		
<b>Property Type</b>	<b>Number</b>	
Application Number:	12652282	
Application Number:	14683991	
Patent Number:	9028879	
Patent Number:	8933022	
Application Number:	15188231	
Application Number:	15010395	
Application Number:	15068350	
Application Number:	16855966	
Application Number:	15693223	
Application Number:	17224009	
Patent Number:	9675702	
Patent Number:	9597404	
Patent Number:	9119835	
Patent Number:	10245325	
Application Number:	16359878	
Patent Number:	8062677	
Application Number:	16560826	
Application Number:	16681285	
Application Number:	17244442	

PATENT

Property Type	Number
Application Number:	17222953
Application Number:	15348188
PCT Number:	US2012027342
PCT Number:	US2016038513
PCT Number:	US2017049757
PCT Number:	US2008052352
PCT Number:	US2008056545
PCT Number:	US2019049915
PCT Number:	US2019060932
PCT Number:	US2021025836

#### CORRESPONDENCE DATA

**Fax Number:** (202)677-4945

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 202.677.4030

**Email:** IP.Docketing@AGG.com

**Correspondent Name:** ARNALL GOLDEN GREGORY LLP

**Address Line 1:** 1775 PENNSYLVANIA AVENUE NW

**Address Line 2:** SUITE 1000

**Address Line 4:** WASHINGTON, D.C. 20006

**ATTORNEY DOCKET NUMBER:** 37426 TO 37466 TRANSFER

**NAME OF SUBMITTER:** BETH DONOVAN

**SIGNATURE:** /Beth Donovan/

**DATE SIGNED:** 07/21/2021

#### Total Attachments: 12

source=JDS\_to\_N21\_Assignment#page1.tif

source=JDS\_to\_N21\_Assignment#page2.tif

source=JDS\_to\_N21\_Assignment#page3.tif

source=JDS\_to\_N21\_Assignment#page4.tif

source=JDS\_to\_N21\_Assignment#page5.tif

source=JDS\_to\_N21\_Assignment#page6.tif

source=JDS\_to\_N21\_Assignment#page7.tif

source=JDS\_to\_N21\_Assignment#page8.tif

source=JDS\_to\_N21\_Assignment#page9.tif

source=JDS\_to\_N21\_Assignment#page10.tif

source=JDS\_to\_N21\_Assignment#page11.tif

source=JDS\_to\_N21\_Assignment#page12.tif

## ASSIGNMENT

**WHEREAS, JDS Therapeutics, LLC**, a corporation organized under and pursuant to the laws of Delaware having its principal place of business at 500 Mamaroneck Ave., Suite 510, Harrison, New York 10528 (hereinafter referred to as Assignor), is the sole and exclusive owner, by assignment, of the Patent Applications listed in Schedule A; and

**WHEREAS, NUTRITION 21, LLC**, a Limited Liability Company organized under and pursuant to the laws of New York having its principal place of business at 500 Mamaroneck Ave., Suite 510, Harrison, New York 10528 (hereinafter referred to as Assignee), is desirous of acquiring the right, title and interest in, to and under said Patent Applications and the inventions covered thereby;

**NOW, THEREFORE**, in consideration of and in exchange for the sum of One Dollar (\$1.00) and other good and valuable consideration, receipt of which is hereby acknowledged, the said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to the said Assignee, the entire right, title and interest for the United States of America and all other countries in and to said applications for all original, divisional, continuation, continuation-in-part, substitute or reissue applications and patents applied for or granted therefore in the United States of America and all other countries on the attached list of *Schedule A*, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue all patents on *Schedule A* to said assignee herein, as assignee of the entire interest therein; and the undersigned for itself and its legal representatives, heirs and assigns does hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, continuation-in-part, reissue and other applications for Letters Patent and all assignments thereof to said assignee or its assigns, to communicate to said assignee or its representatives all facts known to the undersigned respecting said inventions listed on *Schedule A* whenever requested, to testify in any interferences or other legal proceedings in which any of said applications or patents may become involved, to sign all lawful papers, make all rightful oaths, and do generally everything necessary to aid assignee, its successors, assigns and nominees to obtain patent protection for said inventions listed on *Schedule A* in the United States of America and all other countries, the expenses incident to said applications listed on *Schedule A* to be borne and paid by said assignee.

# **SCHEDULE A**

<b>Country Name</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Title</b>
United States of America	12/652282	01/05/2010			Chromium Complexes For Improvement Of Memory And Cognitive Function
European Patent Convention	19160376.0	06/30/2010			Chromium Complexes As Enhancers Of Brain Glucose Transporters
United States of America	14/683991	04/10/2015			Chromium Complexes As Enhancers Of Brain Glucose Transporters
Switzerland	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Czech Republic	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Germany	602010058614.6	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
European Patent Convention	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Spain	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
France	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
United Kingdom	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Ireland	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Liechtenstein	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Netherlands	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
Poland	10794738.4	06/30/2010	2448412	05/01/2019	Chromium Complexes As Enhancers Of Brain Glucose Transporters
United States of America	13/380940	12/27/2011	9028879	05/12/2015	Chromium Complexes As Enhancers Of Brain Glucose Transporters
Patent Cooperation Treaty	PCT/US2010/040679	06/30/2010			Chromium Complexes As Enhancers Of Brain Glucose Transporters
Australia	2012223282	03/01/2012	2012223282	05/18/2017	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
Canada	2828572	03/01/2012	2828572	02/23/2021	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
China (People's Republic)	201280020399.9	03/01/2012	ZL201280020399.9	04/27/2016	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
European Patent Convention	12709222.9	03/01/2012			Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
Israel	228209	03/01/2012	228209	09/01/2020	A Composition Comprising A Chromium-Insulin Complex And Uses Therefor For Treating A Glucose Metabolism-Related Disease Or Disorder
India	8069/DELNP/2013	03/01/2012			Compositions Of

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
					Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
Japan	2013-556874	03/01/2012	6152346	06/02/2017	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
Korea, Republic of	10-2013-7025794	03/01/2012	10-1836957	03/05/2018	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
Mexico	MX/a/2013/009948	03/01/2012	344925	01/11/2017	Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
United States of America	13/409960	03/01/2012	8933022	01/13/2015	Methods And Compositions For The Treatment And Prevention Of Hypoglycemia And Related Disorders
Patent Cooperation Treaty	PCT/US2012/027342	03/01/2012			Compositions Of Insulin And Chromium For The Treatment And Prevention Of Diabetes, Hypoglycemia And Related Disorders
United States of America	15/348188	11/10/2016			Topical Arginine-Silicate-Inositol For Wound Healing
United Kingdom	2019331.4	06/21/2016			Chromium Histidinate And Chromium Picolinate Complexes

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
United Kingdom	1800283.2	06/21/2016	2556247	03/03/2021	Chromium Histidinate And Chromium Picolinate Complexes
United States of America	15/188231	06/21/2016			Chromium Histidinate And Chromium Picolinate Complexes
Patent Cooperation Treaty	PCT/US2016/038513	06/21/2016			Chromium Histidinate And Chromium Picolinate Complexes
United States of America	15/010395	01/29/2016			Chromium Compositions For The Treatment Or Prevention Of Diabetic Retinopathy
United States of America	15/068350	03/11/2016			Arginine Silicate For Periodontal Disease
United States of America	16/855966	04/22/2020			Magnesium Biotinate Compositions And Methods Of Use
Australia	2017318672	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
Canada	3035584	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
China (People's Republic)	201780067650.X	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
European Patent Convention	17847596.8	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
United Kingdom	1904540.0	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
Japan	2019-533293	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
Mexico	MX/a/2019/002468	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
United States of America	15/693223	08/31/2017			Magnesium Biotinate Compositions And Methods Of Use
Patent	PCT/US2017/0497	08/31/2017			Magnesium Biotinate

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
Cooperation Treaty	57				Compositions And Methods Of Use
Canada	2931881	01/29/2008	2931881	12/11/2018	Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Canada	3021932	10/24/2018	3021932	12/15/2020	Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
United States of America	17/224009	04/06/2021			Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Australia	2008210586	01/29/2008	2008210586	10/17/2013	Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Canada	2676977	01/29/2008	2676977	10/04/2016	Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Mexico	MX/a/2009/008135	01/29/2008	327363	01/28/2015	Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Patent Cooperation Treaty	PCT/US2008/052352	01/29/2008			Use Of Chromium Histidinate For Treatment Of Cardiometabolic Disorders
Canada	3013149	08/02/2018			Methods And Compositions For The Sustained Release Of Chromium
Switzerland	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium



<b>Country Name</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Title</b>
Czech Republic	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Germany	602008063543.0	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
European Patent Convention	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Spain	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
France	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
United Kingdom	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Ireland	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Liechtenstein	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Netherlands	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
Poland	16160735.3	03/16/2016	3050568	12/02/2020	Methods And Compositions For The Sustained Release Of Chromium
United States of America	14/805136	07/21/2015	9675702	06/13/2017	Methods And Compositions For The Sustained Release Of Chromium
United	14/805034	07/21/2015	9597404	03/21/2017	Methods And

<b>Country Name</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Title</b>
States of America					Compositions For The Sustained Release Of Chromium
United States of America	13/300059	11/18/2011	9119835	09/01/2015	Methods And Compositions For The Sustained Release Of Chromium
United States of America	15/620542	06/12/2017	10245325	04/02/2019	Methods And Compositions For The Sustained Release Of Chromium
United States of America	16/359878	03/20/2019			Methods And Compositions For The Sustained Release Of Chromium
United States of America	12/340257	12/19/2008	8062677	11/22/2011	Methods And Compositions For The Sustained Release Of Chromium
Canada	2681158	03/11/2008	2681158	09/18/2018	Methods And Compositions For The Sustained Release Of Chromium
Switzerland	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Czech Republic	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Germany	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
European Patent Convention	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Spain	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
France	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
					Sustained Release Of Chromium
United Kingdom	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Ireland	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Liechtenstein	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Netherlands	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Poland	08731918.2	03/11/2008	2134351	04/27/2016	Methods And Compositions For The Sustained Release Of Chromium
Patent Cooperation Treaty	PCT/US2008/056545	03/11/2008			Methods And Compositions For The Sustained Release Of Chromium
Australia	2019336216	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
Canada	3112297	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
China (People's Republic)	201980058488.4	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
European Patent Convention	19857143.2	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
United Kingdom	2104868.1	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin

Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
					Compositions
Japan	2021-512754	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
Korea, Republic of	10-2021-7009774	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
Mexico	MX/A/2021/002754	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
United States of America	16/560826	09/04/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
Patent Cooperation Treaty	PCT/US2019/049915	09/06/2019			Treatment Of Autism And Autism Spectrum Disorders With Biotin Compositions
United States of America	16/681285	11/12/2019			Treatment Of Autoimmune Disorders, Such As Relapsing Remitting Multiple Sclerosis And Clinically Isolated Syndrome With Biotin Compositions
Patent Cooperation Treaty	PCT/US2019/060932	11/12/2019			Treatment Of Autoimmune Disorders, Such As Relapsing Remitting Multiple Sclerosis And Clinically Isolated Syndrome With Biotin Compositions
United States of America	17/244442	04/29/2021			Method And Composition For Enhancing The Quality And Benefits Of Sleep
United States of America	17/222953	04/05/2021			Method And Composition For Enhancing The Quality And Benefits Of Sleep


Country Name	Application No.	Filing Date	Patent Number	Issue Date	Title
Patent Cooperation Treaty	PCT/US2021/025836	04/05/2021			Method And Composition For Enhancing The Quality And Benefits Of Sleep

JDS Therapeutics, LLC

Date:

7/15/21

Signature



Sara O'Brien  
General Counsel  
JDS Therapeutics, LLC

ASSIGNEE hereby accepts receipt of the entire right, title and interest in and to  
the PATENTS AND PATENT APPLICATIONS.

NUTRITION 21, LLC

By: 

Sara O'Brien

Title: General Counsel

Date: 7/15/21